ONCOLOGY.
No. 6
The Thomas/von Gunten Article Reviewed
Treatment of Dyspnea in Cancer Patients
By
Lauren Shaiova, MD
Attending Physician, Department of Pain
Medicine and Palliative Care, Beth Israel Medical Center, New York, New York
Russell K. Portenoy, MD
Professor of Neurology, Department of Pain
Medicine and Palliative Care, Beth Israel Medical Center, New York, New York
|
June 1, 2002
Thomas and von Gunten note the wide variation in presentations, etiologies,
and pathophysiologies of dyspnea in cancer patients. Potential therapies are
equally diverse. Clinicians should perform comprehensive assessments and
exercise judgment in selecting from a broad spectrum of disease-modifying and
symptomatic therapies.
1. Ventafridda V, Spolodi E, De Conno F: Control of dyspnea in advance cancer
patients. Chest 98:1544-1545, 1990.
2. Cherny NI, Portenoy RK: Sedation in management of refractory symptoms:
Guidelines for evaluation and treatment. J Palliat Care 10:31-39, 1994.
3. Bruera E, MacMillin K, Pither J, et al: The effects of morphine on dyspnea
of terminal cancer patients. J Pain Symptom Manage 5:341-344, 1990.
4. Dudgeon DJ, Lertzman M, Askew GR: Physiological changes and clinical
correlations of dyspnea in cancer outpatients. J Pain Symptom Manage 21:373-379,
2001.